Cargando…

Tanshinone IIA potentiates the efficacy of imatinib by regulating the AKT-MDM2-P53 signaling pathway in Philadelphia chromosome-positive acute lymphoblastic leukemia

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is triggered by breakpoint cluster region-abelson leukemia virus (BCR/ABL) kinase. Targeting BCR/ABL kinase with tyrosine kinase inhibitors combined with chemotherapy is the standard first-line therapy for Ph+ ALL. Imatinib and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Yong, Wang, Fang-Fang, Xiang, Bing, Ma, Hong-Bing, Gong, Yu-Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607239/ https://www.ncbi.nlm.nih.gov/pubmed/34820006 http://dx.doi.org/10.3892/ol.2021.13125

Ejemplares similares

Imatinib Treatment Alone in Philadelphia-Positive Acute Lymphoblastic Leukemia: Is It Enough?
por: Ay, Yilmaz, et al.
Publicado: (2010)

Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood
por: Koo, Hong Hoe
Publicado: (2011)

Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia
por: Singh, Surjit, et al.
Publicado: (2016)

Imatinib-based therapy in adult Philadelphia chromosome-positive acute lymphoblastic leukemia: A case report and literature review
por: ZHANG, LI, et al.
Publicado: (2015)

Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China
por: Cao, Wang, et al.
Publicado: (2022)

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults
por: Saleh, Khalil, et al.
Publicado: (2022)

Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison
por: Ribera, Josep-Maria, et al.
Publicado: (2023)

Inhibition of MDM2 by Nilotinib Contributes to Cytotoxicity in Both Philadelphia-Positive and Negative Acute Lymphoblastic Leukemia
por: Zhang, Hailong, et al.
Publicado: (2014)

Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Bernt, Kathrin M., et al.
Publicado: (2014)

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
por: Cazzaniga, Giovanni, et al.
Publicado: (2018)

Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia
por: Kenderian, S S, et al.
Publicado: (2013)

Uterine relapse of Philadelphia chromosome-negative acute lymphoblastic leukemia
por: Kawano, Noriaki, et al.
Publicado: (2020)

Current treatment strategies for Philadelphia chromosome-positive adult acute lymphoblastic leukemia
por: Park, Han-Seung
Publicado: (2020)

Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Monitoring Ponatinib in a Child with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Tanimura, Kazuki, et al.
Publicado: (2021)

Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2022)

Metabolism of Tanshinone IIA, Cryptotanshinone and Tanshinone I from Radix Salvia Miltiorrhiza in Zebrafish
por: Wei, Yingjie, et al.
Publicado: (2012)

Favorable outcome of allogeneic hematopoietic stem cell transplantation followed by post-transplant treatment with imatinib in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Byun, Ye Jee, et al.
Publicado: (2015)

Outcome and prognostic factors of children with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib followed by allogeneic hematopoietic cell transplantation in first remission
por: Shin, Juae, et al.
Publicado: (2019)

Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China
por: Chen, Min, et al.
Publicado: (2023)

Tanshinone IIA: A Review of its Anticancer Effects
por: Fang, Zhong‐ying, et al.
Publicado: (2021)

Oligoclonal Immunoglobulin Gene Rearrangements in Philadelphia Chromosome‐positive Common Acute Lymphoblastic Leukemia
por: Ikeda, Takeshi, et al.
Publicado: (1990)

Machine learning-aided risk stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Nishiwaki, Satoshi, et al.
Publicado: (2021)

The role of stem cell transplantation in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Ribera, Jose-Maria, et al.
Publicado: (2018)

Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Hohtari, Helena, et al.
Publicado: (2022)

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients
por: Trino, Stefania, et al.
Publicado: (2016)

Effect of Supplementation of Tanshinone IIA and Sodium Tanshinone IIA Sulfonate on the Anticancer Effect of Epirubicin: An In Vitro Study
por: Chan, Szu-Erh, et al.
Publicado: (2011)

Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta‐analysis
por: Zeng, Qiang, et al.
Publicado: (2021)

Oncogene-independent resistance in Philadelphia chromosome - positive (Ph(+)) acute lymphoblastic leukemia (ALL) is mediated by activation of AKT/mTOR pathway
por: Mian, Afsar Ali, et al.
Publicado: (2021)

PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
por: Jabbour, E., et al.
Publicado: (2022)

How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia
por: Frisch, Avraham, et al.
Publicado: (2019)

Philadelphia chromosome-like acute lymphoblastic leukemia. Still a pending matter
por: Ribera, Josep-Maria
Publicado: (2021)

Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Fedullo, Anna Lucia, et al.
Publicado: (2019)

Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome‐positive acute lymphoblastic leukemia
por: Akahoshi, Yu, et al.
Publicado: (2019)

Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia
por: Stock, Wendy, et al.
Publicado: (2020)

An Unusual Presentation of Extramedullary Relapse Following Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Daghri, Sanae, et al.
Publicado: (2022)

Dasatinib-based 2-step induction for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Sugiura, Isamu, et al.
Publicado: (2022)

A chemotherapy-free regimen for Philadelphia chromosome-positive acute lymphoblastic leukemia: are we there yet?
por: Ofran, Yishai
Publicado: (2021)

Preparation and characterisation of solid dispersions of tanshinone IIA, cryptotanshinone and total tanshinones
por: Zhai, Xifeng, et al.
Publicado: (2017)

Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia
por: Li, Shaoguang
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_tsvj8id88gjcu8a1r7kqrko7p0